The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis
A Pilot Project to Assess the Effect of High-intensity Interval Training in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis
1 other identifier
interventional
12
1 country
2
Brief Summary
This pilot study aims to investigate whether 6 weeks of twice weekly High-intensity Interval Training (HIT) results in improvements in disease-specific measures, feelings of general well-being, physical fitness and cognitive function in patients with non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Oct 2015
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 10, 2015
CompletedFirst Posted
Study publicly available on registry
August 19, 2015
CompletedStudy Start
First participant enrolled
October 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2016
CompletedResults Posted
Study results publicly available
May 4, 2018
CompletedMay 4, 2018
May 1, 2018
8 months
August 10, 2015
December 5, 2016
May 3, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (13)
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
calculation of insulin resistance via formula: fasting insulin (mIU/L) x fasting glucose (mg/dL)/405 normal insulin resistance -HOMA score \<3 moderate insulin resistance -HOMA score 3-5 severe insulin resistance -HOMA score \>5 Assessed at baseline, after 6 week control period and within 1 week of completing 6 weeks HIT
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Oral Glucose Tolerance Test
measurement of capillary samples for glucose at time 0, followed by every 20 minutes for 2 hours following ingestion of 75g glucose. Results graphed against time, then area under the curve calculated for each of the 3 assessments.
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
AST: ALT Ratio
ratio of liver enzymes aspartate aminotransferase (AST) to alanine aminotransferase (ALT). used as a diagnostic aid e.g. AST:ALT of more than 2:1 is characteristic of alcoholic liver disease whereas fatty steatosis and many other causes of liver disease, ratio is less than or equal to 1. Ratio may rise as fibrosis and cirrhosis develop in viral hepatitis.
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
FIB-4
calculated from AST, ALT, platelets and participant's age and used to estimate amount of fibrosis in liver. Fib-4 score of \<1.45 has negative predictive value of 90% for advanced fibrosis.
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Body Fat Mass Estimated Via Bioimpedance
total body fat and trunk fat estimated via bioimpedance measured after overnight fast, expressed as percentage
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Blood Pressure
taken with participant supine, measured on left arm
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
General Well-being as Assessed by SF-36 Questionnaire
Assessment of: physical functioning, social functioning, mental health, pain, change in health, physical role limitation, mental role limitation, energy and vitality, health perception over preceding 4 weeks (other than change in health, which is a comparison to health the preceding year), expressed as a transformed score range 0-100, with a higher score indicating better function/freedom from pain etc
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Short-term Memory Recall
testing of verbal word presentation-immediate recall of 10 words (60 seconds for recall) Maximum =10, minimum =0
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Estimated VO2 Max
VO2 max estimated via submaximal exercise test-submaximal treadmill walking test Calculated via formula: VO2max= 15.1+21.8 x speed (miles per hour) - 0.327 x heart rate (beats per minute) - 0.263 x speed x age (years) + 0.00504 x heart rate x age + 5.98 x gender (0=female, 1=male)
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Physical Function-"Get up and go" Test
participant will be timed standing up from chair unaided,walking 30m, turning round and returning to a seated position on the chair, the average time of 3 attempts will be recorded.
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Ankle Brachial Pressure Index (ABPI)
ratio of blood pressure in left arm and right ankle
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Long-term Memory Recall
testing of verbal word presentation-delayed recall of 10 words 10 minutes after words initially presented (within 60 seconds). Maximum= 10 words, minimum = no words
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Executive Function (Verbal Fluency Test)
written verbal fluency test: participant asked to write down as many English words as possible within 60 seconds, starting with a particular letter of the alphabet, excluding proper nouns or plurals. Baseline assessment-letter A Post Control assessment -letter S After HIT assessment -letter F
Baseline, Follow up at 6 Weeks and following HIT intervention at 12 Weeks
Study Arms (1)
High-intensity Interval Training (HIT)
EXPERIMENTAL6 week control period with no intervention then 6 weeks of twice weekly HIT
Interventions
2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5\&6, 8 sprints in sessions 7\&8, 9 sprints in sessions 9\&10 and 10 sprints in sessions 11\&12.
Eligibility Criteria
You may qualify if:
- clinical diagnosis of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis
- attending a specialist liver clinic at Ninewells Hospital, Dundee
You may not qualify if:
- unstable cardiovascular disease
- uncontrolled arrhythmias
- structural cardiac abnormalities
- uncontrolled diabetes
- other uncontrolled metabolic abnormalities
- severe orthopaedic condition that would prohibit exercise
- severe pulmonary condition that would prohibit exercise
- any other poorly controlled medical condition.
- resting systolic blood pressure above 160 mm Hg
- resting diastolic blood pressure above 90 mm Hg
- symptomatic postural drop in blood pressure greater than 20 mm Hg
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Bathlead
- Abertay Universitycollaborator
Study Sites (2)
Abertay University
Dundee, DD1 1HG, United Kingdom
Ninewells Hospital
Dundee, DD1 9SY, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr Niels Vollaard
- Organization
- University of Striling
Study Officials
- PRINCIPAL INVESTIGATOR
Niels BJ Vollaard, PhD
University of Bath
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Masking Details
- No Masking, this was not possible with this study design.
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer in Human and Applied Physiology
Study Record Dates
First Submitted
August 10, 2015
First Posted
August 19, 2015
Study Start
October 1, 2015
Primary Completion
June 1, 2016
Study Completion
June 1, 2016
Last Updated
May 4, 2018
Results First Posted
May 4, 2018
Record last verified: 2018-05
Data Sharing
- IPD Sharing
- Will not share
There is no reason to share the IPD.